Delivery Order SPE2DR25D3301-SPE2DR26F21JM
- Not listed
- The Defense Logistics Agency awarded a $33,334.25 delivery order to AmerisourceBergen Drug Corp for the supply of Everolimus 1 mg tablets (60-count units) under a firm fixed price contract. The delivery order was issued on December 17, 2025, with an ultimate completion date of December 18, 2025, and the work will be performed at the contractor's facility in Conshohocken, Pennsylvania. This non-competitive award represents a continuation of the government's pharmaceutical procurement through...
- The Defense Logistics Agency awarded a $14.9K delivery order to AmerisourceBergen Drug Corp on January 15, 2026, for the supply of Everolimus 10 mg tablets (30-count packaging) with a completion date of January 16, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- The U.S. Defense Department's Medical Supply Chain awarded a $18,147.63 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Everolimus 10 mg tablets in quantities of 30. The contract was competitively awarded without set-aside restrictions under a firm fixed-price delivery order mechanism, with an ultimate completion date of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a prime pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $49,240.83 to AmerisourceBergen Drug Corp for the supply of Everolimus 1 mg tablets in unit-dose packaging (60-count) with a firm fixed-price structure. The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by January 15, 2026, and will be fulfilled from the awardee's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Everolimus 5 mg tablets (30-count) under a firm fixed-price contract valued at $5,473.37, with an ultimate completion date of November 21, 2025. This non-set-aside award was competitively procured and represents a single delivery order transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. The contract will be performed at the vendor's corporate office...
- The Defense Logistics Agency awarded a $3,977.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Everolimus 0.75 mg, with a completion deadline of September 30, 2025. This non-set-aside contract was competitively awarded and performed at the contractor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Everolimus 5 mg tablets (30-count packages) with a ceiling value of $44,765.09. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 13, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Everolimus 0.75 mg tablets (60-count units) with a contract value of $7,139.43. This firm fixed-price delivery order, issued on May 27, 2025, with an ultimate completion date of May 28, 2025, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competed delivery order under AmerisourceBergen's existing contract vehicle with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Everolimus 10 mg tablets (30-count) valued at $19,124.79 under a firm fixed-price contract type. The delivery order was competitively awarded without set-aside provisions and carries an ultimate completion date of October 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This award represents a continuation of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Everolimus 10 mg tablets (quantity 30) under a firm fixed-price contract valued at $12,749.86, with an ultimate completion date of December 12, 2025. This non-set-aside award represents a competitively awarded transaction for pharmaceutical supply supporting federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F21JMDelivery Order
The Defense Logistics Agency awarded a $10,950.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Everolimus 5 mg tablets (30-count units) on January 27, 2026, with an ultimate completion date of January 28, 2026. This competitively awarded, non-set-aside contract was performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a task order issued under AmerisourceBergen's parent company, Cencora, Inc.'s substantially larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical and medical supply support to military healthcare programs globally. AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor within the federal supply chain, serving the military and veteran healthcare systems through DLA's medical procurement operations. The Everolimus product supplied under this delivery order supports oncology and immunosuppressant treatment needs across military treatment facilities and federal healthcare institutions. The parent IDC with DLA encompasses an extensive portfolio of specialty medications, generic and brand-name drugs, vaccines, and medical devices across multiple therapeutic domains, demonstrating Cencora's established capability to fulfill government contracts for essential pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.0k | 1/26/26 |